ABSTRACT
SARS-CoV-2 attacks various organs, most destructively the lung, and cellular entry requires two host cell surface proteins: ACE2 and TMPRSS2. Downregulation of one or both of these is thus a potential therapeutic approach for COVID-19. TMPRSS2 is a known target of the androgen receptor, a ligand-activated transcription factor; androgen receptor activation increases TMPRSS2 levels in various tissues, most notably prostate. We show here that treatment with the antiandrogen enzalutamide-a well-tolerated drug widely used in advanced prostate cancer-reduces TMPRSS2 levels in human lung cells and in mouse lung. Importantly, antiandrogens significantly reduced SARS-CoV-2 entry and infection in lung cells. In support of this experimental data, analysis of existing datasets shows striking co-expression of AR and TMPRSS2, including in specific lung cell types targeted by SARS-CoV-2. Together, the data presented provides strong evidence to support clinical trials to assess the efficacy of antiandrogens as a treatment option for COVID-19.
Subject(s)
Androgen Antagonists/pharmacology , Benzamides/pharmacology , COVID-19 Drug Treatment , Nitriles/pharmacology , Phenylthiohydantoin/pharmacology , Serine Endopeptidases/metabolism , Virus Internalization/drug effects , Angiotensin-Converting Enzyme 2/chemical synthesis , Angiotensin-Converting Enzyme 2/metabolism , Animals , COVID-19/metabolism , COVID-19/virology , Down-Regulation/drug effects , Female , Humans , Lung/metabolism , Lung/virology , Male , Mice , SARS-CoV-2/drug effects , Serine Endopeptidases/geneticsABSTRACT
Researchers the world over are working to find the treatments needed to reduce the negative effects of coronavirus disease 2019 (COVID-19) and improve the current prognosis of patients. Several drugs that are often used in dermatology are among the potentially useful treatments: ivermectin, antiandrogenic agents, melatonin, and the antimalarial drugs chloroquine and hydroxychloroquine. These and other agents, some of which have proven controversial, are being scrutinized by the scientific community. We briefly review the aforementioned dermatologic drugs and describe the most recent findings relevant to their use against COVID-19.
Subject(s)
COVID-19 Drug Treatment , SARS-CoV-2 , Androgen Antagonists/pharmacology , Androgen Antagonists/therapeutic use , Antimalarials/pharmacology , Antimalarials/therapeutic use , Antioxidants/pharmacology , Antioxidants/therapeutic use , Antiparasitic Agents/pharmacology , Antiparasitic Agents/therapeutic use , COVID-19/mortality , Chloroquine/pharmacology , Chloroquine/therapeutic use , Cinchona/chemistry , Humans , Hydroxychloroquine/pharmacology , Hydroxychloroquine/therapeutic use , Ivermectin/pharmacology , Ivermectin/therapeutic use , Melatonin/pharmacology , Melatonin/therapeutic use , Virus Internalization/drug effectsSubject(s)
Androgen Antagonists/pharmacology , Androgens/metabolism , Betacoronavirus , Coronavirus Infections , Drug Repositioning , Pandemics , Pneumonia, Viral , Prostatic Neoplasms , Betacoronavirus/drug effects , Betacoronavirus/physiology , COVID-19 , Clinical Trials as Topic , Coronavirus Infections/epidemiology , Coronavirus Infections/prevention & control , Coronavirus Infections/therapy , Drug Repositioning/methods , Drug Repositioning/trends , Humans , Male , Mortality , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/prevention & control , Pneumonia, Viral/therapy , Prostatic Neoplasms/epidemiology , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/therapy , Risk Factors , SARS-CoV-2 , Severity of Illness Index , Sex FactorsABSTRACT
The severe form of COVID-19 has significant sex disparities, with high fatalities commonly reported among males than females. The incidence of COVID-19 has also been higher in males compared with their female counterparts. This trend could be attributed to a better responsive and robust immune system in females. Cytokine storm is one of the pathophysiological features of severe COVID-19, and it occurs as a result of over-activation of immune cells leading to severe inflammation and tissue damage. Nevertheless, it is well modulated in females compared to their male counterparts. Severe inflammation in males is reported to facilitate progression of mild to severe COVID-19. The sex hormones, estrogens and androgens which exist in varying functional levels respectively in females and males are cited as the underlying cause for the differential immune response to COVID-19. Evidence abounds that estrogen modulate the immune system to protect females from severe inflammation and for that matter severe COVID-19. On the contrary, androgen has been implicated in over-activation of immune cells, cytokine storm and the attendant severe inflammation, which perhaps predispose males to severe COVID-19. In this review efforts are made to expand understanding and explain the possible roles of the immune system, the sex hormones and the angiotensin-converting enzyme (ACE) systems in male bias to severe COVID-19. Also, this review explores possible therapeutic avenues including androgen deprivation therapy (ADT), estrogen-based therapy, and ACE inhibitors for consideration in the fight against COVID-19.
Subject(s)
Betacoronavirus/physiology , Coronavirus Infections/epidemiology , Pandemics , Pneumonia, Viral/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Androgen Antagonists/pharmacology , Androgen Antagonists/therapeutic use , Angiotensin-Converting Enzyme 2 , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Animals , COVID-19 , Child , Child, Preschool , Coronavirus Infections/complications , Coronavirus Infections/drug therapy , Coronavirus Infections/immunology , Coronavirus Infections/therapy , Disease Susceptibility , Female , Gonadal Steroid Hormones/physiology , Humans , Immunity, Innate , Infant , Infant, Newborn , Inflammation , Male , Mice , Middle Aged , Peptidyl-Dipeptidase A/physiology , Pneumonia, Viral/complications , Pneumonia, Viral/immunology , Pneumonia, Viral/therapy , Prostatic Neoplasms/complications , Prostatic Neoplasms/drug therapy , Protein Disulfide-Isomerases/physiology , Receptors, Cell Surface/physiology , Receptors, Virus/physiology , SARS-CoV-2 , Sex Distribution , Smoking/adverse effects , Young Adult , COVID-19 Drug TreatmentABSTRACT
In coronavirus disease-19 (COVID-19), four major factors have been correlated with worse prognosis: aging, hypertension, obesity, and exposure to androgen hormones. Angiotensin-converting enzyme-2 (ACE2) receptor, regulation of the renin-angiotensin-aldosterone system (RAAS), and transmembrane serine protease 2 (TMPRSS2) action are critical for the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) cell entry and infectivity. ACE2 expression and RAAS are abnormal in hypertension and obesity, while TMPRSS2 is overexpressed when exposed to androgens, which may justify why these factors are overrepresented in COVID-19. Among therapeutic targets for SARS-CoV-2, we hypothesized that spironolactone, a long used and safe mineralocorticoid and androgen receptors antagonist, with effective anti-hypertensive, cardioprotective, nephroprotective, and anti-androgenic properties may offer pleiotropic actions in different sites to protect from COVID-19. Current data shows that spironolactone may concurrently mitigate abnormal ACE2 expression, correct the balances membrane-attached and free circulating ACE2 and between angiotensin II and Angiotensin-(1-7) (Ang-(1-7)), suppress androgen-mediated TMPRSS2 activity, and inhibit obesity-related RAAS dysfunctions, with consequent decrease of viral priming. Hence, spironolactone may provide protection from SARS-CoV-2, and has sufficient plausibility to be clinically tested, particularly in the early stages of COVID-19.